BLUE - bluebird bio Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before May 28 2024 to Discuss Your Rights – BLUE | Benzinga
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE).
Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=81199&from=3
CLASS PERIOD: April 24, 2023 to December 8, 2023
ALLEGATIONS: According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history ...